Dashboard
Manage Tickers

VTGN


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

vistagen-therapeutics-q1-2025-adj-eps-035-beats-041-estimate-sales-8400k-miss-30000k-estimate
VistaGen Therapeutics Q1 2025 Adj EPS $(0....
08/13/2024 20:23:27

VistaGen Therapeutics (NASDAQ:VTGN) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of...

vistagen-expands-global-intellectual-property-portfolio-with-new-patents-for-ph80-nasal-spray-investigational-treatment-for-migraine-hot-flashes-due-to-menopause-premenstrual-dysphoric-disorder-and-dysmenorrhea
Vistagen Expands Global Intellectual Prope...
07/09/2024 12:34:27

vistagen-reports-fy24-net-loss-of-294m-vs--592m-last-year
Vistagen Reports FY24 Net Loss Of $(29.4)M...
06/11/2024 20:23:05

Cash and cash equivalents were $119.2 million as of March 31, 2024.

vistagen-announces-results-from-phase-2a-pilot-study-of-ph15-for-improvement-of-psychomotor-impairment-caused-by-mental-fatigue
Vistagen Announces Results From Phase 2A P...
04/25/2024 12:40:28

PH15 nasal spray demonstrates statistically significant efficacy versus placebo and caffeine in a placebo-controlled Phase 2A p...

vistagen-initiates-palisade-3-phase-3-study-of-fasedienol-for-the-acute-treatment-of-social-anxiety-disorder-following-results-of-palisade-2
Vistagen Initiates PALISADE-3 Phase 3 Stud...
04/01/2024 12:31:37

Key study underway in registration-directed PALISADE Phase 3 program for fasedienol in social anxiety disorderSocial anxiety di...

10-health-care-stocks-whale-activity-in-todays-session
10 Health Care Stocks Whale Activity In To...
02/19/2024 17:35:24

vistagen-therapeutics-q3-eps-022-beats-030-estimate-sales-41140k-miss-54450k-estimate
VistaGen Therapeutics Q3 EPS $(0.22) Beats...
02/13/2024 21:31:01

VistaGen Therapeutics (NASDAQ:VTGN) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of...

recap-vistagen-therapeutics-q3-earnings
Recap: Vistagen Therapeutics Q3 Earnings
02/13/2024 21:25:07

earnings-scheduled-for-february-13-2024
Earnings Scheduled For February 13, 2024
02/13/2024 10:05:59

Companies Reporting Before The Bell • LCI Indus (NYSE:LCII) is likely to report quarterly earnings at $0.18 per share on reven...

vistagen-therapeuticss-earnings-a-preview
VistaGen Therapeutics's Earnings: A Preview
02/12/2024 19:01:36

vistagen-receives-notice-from-european-patent-office-of-intention-to-grant-patent-for-av-101-to-treat-neuropathic-pain
Vistagen Receives Notice From European Pat...
12/27/2023 13:30:48

Preclinical data in four well-established preclinical models of pain associated with tissue inflammation and nerve injury demon...

jefferies-upgrades-vistagen-therapeutics-to-buy-raises-price-target-to-15
Jefferies Upgrades Vistagen Therapeutics t...
12/07/2023 10:35:02

Jefferies analyst Andrew Tsai upgrades Vistagen Therapeutics (NASDAQ:VTGN) from Hold to Buy and raises the price target from...

hearing-vistagen-therapeutics-upgraded-from-a-hold-to-a-buy-at-jefferies-price-target-15
Hearing Vistagen Therapeutics Upgraded Fro...
12/07/2023 00:10:59

undervalued-vistagen-therapeutics-analyst-highlights-potential-in-anxiety-treatment
Undervalued VistaGen Therapeutics, Analyst...
12/04/2023 19:39:15

William Blair initiated coverage on VistaGen Therapeutics Inc (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focuse...

anxiety-focused-stock-vistagen-therapeutics-is-an-undervalued-late-stage-neurology-player-analyst
Anxiety-Focused Stock Vistagen Therapeutic...
11/14/2023 19:08:02

Analysts at Stifel recently initiated coverage on Vistagen Therapeutics Inc (NASDAQ: VTGN), emphasizing the potential of its le...

stifel-initiates-coverage-on-vistagen-therapeutics-with-buy-rating-announces-price-target-of-12
Stifel Initiates Coverage On Vistagen Ther...
11/14/2023 17:47:38

Stifel analyst Paul Matteis initiates coverage on Vistagen Therapeutics (NASDAQ:VTGN) with a Buy rating and announces Price ...

vistagen-therapeutics-q2-2024-eps-066-beats-068-estimate-sales-27770k-beat-18000k-estimate
VistaGen Therapeutics Q2 2024 EPS $(0.66) ...
11/09/2023 21:49:21

VistaGen Therapeutics (NASDAQ:VTGN) reported quarterly losses of $(0.66) per share which beat the analyst consensus estimate of...

earnings-scheduled-for-november-9-2023
Earnings Scheduled For November 9, 2023
11/09/2023 11:52:51

Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is expected to report quarterly earnings at $0.30 per share on re...

vistagen-therapeutics-earnings-preview
VistaGen Therapeutics Earnings Preview
11/08/2023 19:01:35

vistagen-to-present-fasedienol-phase-3-data-and-ph80-phase-2a-data-at-upcoming-scientific-conferences
Vistagen To Present Fasedienol Phase 3 Dat...
11/07/2023 13:35:17

Positive top-line results from fasedienol (PH94B) Phase 3 PALISADE-2 trial in social anxiety disorder (SAD) to be presented by ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION